Justin L. Ricker

Bicycle Therapeutics (United Kingdom) — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

26h-index6.6kcitations89works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Histone Deacetylase Inhibitors Research(23), Lung Cancer Treatments and Mutations(17), Acute Myeloid Leukemia Research(12), Chronic Myeloid Leukemia Treatments(12), Peptidase Inhibition and Analysis(12)

Publications89 total

PS5-09-23: A Phase 2 study of zelenectide pevedotin, a Bicycle Drug Conjugate, in patients with NECTIN4 amplified advanced breast cancer (Duravelo-3)
Clinical Cancer Research·2026
628TiP A phase 2 study of zelenectide pevedotin, a bicycle drug conjugate, in patients with NECTIN4 amplified advanced breast cancer (Duravelo-3)
Annals of Oncology·2025
Data from Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
2023Open Access
Supplementary Figures S1 - S3, Table S1 from Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
2023Open Access
Supplementary Figures S1 - S3, Table S1 from Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
2023Open Access
Data from Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
2023Open Access
Supplementary Table S1 from Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-κB and activator protein-1 related mechanisms
2023Open Access
Data from Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-κB and activator protein-1 related mechanisms
2023Open Access
Supplementary Table S1 from Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-κB and activator protein-1 related mechanisms
2023Open Access
Data from Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-κB and activator protein-1 related mechanisms
2023Open Access
Response rate to lenalidomide plus rituximab (R<sup>2</sup>) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.
Journal of Clinical Oncology·2018· 6 cited
PHASE IIIB STUDY OF LENALIDOMIDE PLUS RITUXIMAB FOLLOWED BY MAINTENANCE IN RELAPSED OR REFRACTORY NHL: ANALYSIS OF MARGINAL ZONE LYMPHOMA
Hematological Oncology·2017· 6 citedOpen Access
Phase IIIb randomized study of lenalidomide plus rituximab (R<sup>2</sup>) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).
Journal of Clinical Oncology·2017· 21 cited
Vorinostat
2017
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Cancer Discovery·2016· 1.0k citedOpen Access
Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib
Lung Cancer·2015· 18 cited
Abstract 2834: BH3 profiling predicts clinical response in a phase II clinical trial of ABT-199 (GDC-0199) in acute myeloid leukemia
Cancer Research·2015· 3 cited
Reply to M. Bouattour et al
Journal of Clinical Oncology·2015
Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkin’s Lymphoma (NHL).
Journal of Clinical Oncology·2015· 3 cited
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies
Investigational New Drugs·2015· 21 cited
page 1 of 5Next →

Frequent Co-authors

Dawn M. Carlson(15), Jiang Qian(9), Stanley R. Frankel(7), Syed Rizvi(7), Cong Chen(6), Madeleine Duvic(5), Evelyn McKeegan(5), Mark D. McKee(5), Sophia Randolph(5), Carter Van Waes(5), Judy H. Chiao(4), Elise A. Olsen(4), Theresa Pacheco(4), Sareeta Parker(4), Linda Sun(4), Zhong Chen(4), Rajendra Pradhan(4), Ross A. Soo(4), Victoria M. Richon(3), Ming Zhu(3)